PD52-05 ASSESSING PAM50 MOLECULAR SUBTYPES BY RACE AND OUTCOMES IN MEN WITH LOCALIZED PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Markers II (PD52)1 Apr 2020PD52-05 ASSESSING PAM50 MOLECULAR SUBTYPES BY RACE AND OUTCOMES IN MEN WITH LOCALIZED PROSTATE CANCER Yaw Nyame*, Xiaoyu Wang, Kristina Jordahl, James Dai, Dean Troyer, Raymond Lance, Jonathan Wright, and Janet Stanford Yaw Nyame*Yaw Nyame* More articles by this author , Xiaoyu WangXiaoyu Wang More articles by this author , Kristina JordahlKristina Jordahl More articles by this author , James DaiJames Dai More articles by this author , Dean TroyerDean Troyer More articles by this author , Raymond LanceRaymond Lance More articles by this author , Jonathan WrightJonathan Wright More articles by this author , and Janet StanfordJanet Stanford More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000954.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Molecular subtyping using the PAM50 classifier has demonstrated associations with disease prognosis and treatment response in breast and prostate cancer. This study aims to evaluate whether there are differences between African American (AA) and white men in the predominant cellular lineage of prostate tumors. METHODS: This is an analysis of a pooled cohort comprised of AA or white men with localized prostate cancer treated with radical prostatectomy from the Fred Hutchinson Cancer Research Center (n=501), Eastern Virginia Medical School (n=124), and The Cancer Genome Atlas (n=472). Using previously described PAM50 methodology, a nearest centroid classifier was applied on each dataset and classified tumors into the following three categories based on gene expression data: (1) luminal A, (2) luminal B, and (3) basal. Kaplan-Meier analysis stratified by race was conducted to estimate progression-free survival—defined as freedom from biochemical failure, metastases, or prostate cancer mortality—and prostate cancer specific survival. Statistical significance was calculated using the log-rank test. RESULTS: In total, 1,097 unique patients were evaluated. AA men represented 13% (n=143) of the dataset. Luminal A was the most common subtype among AA men (50.4%) compared to white men (38.4%, p < 0.001). Basal subtype (16.8% vs. 22.9%, p = 0.13) and luminal B (32.9% vs. 38.8%, p = 0.21) were less common among AA men compared to white men, respectively. On univariable analysis, luminal B was associated with lower rates of progression-free survival and prostate cancer specific survival when compared to luminal A and basal tumors (Figure 1, both p < 0.01). These observations remained consistent when stratified by race. The 10-year cumulative freedom from disease progression was 52%, 78.9%, and 73.1% among AA men and 62.2%, 73.1%, and 71.3% among white men, for luminal B, luminal A, and basal subtypes respectively. CONCLUSIONS: AA men demonstrated a higher proportion of luminal A tumors; however, AA men with luminal B tumors had the worse clinical outcomes in a pooled dataset of prostatectomy patients. Larger cohorts enriched for AA men are needed to confirm these results and better understand cellular lineage of prostate cancer by race and its impact on treatment response and cancer-specific survival. Source of Funding: none © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e1091-e1091 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Yaw Nyame* More articles by this author Xiaoyu Wang More articles by this author Kristina Jordahl More articles by this author James Dai More articles by this author Dean Troyer More articles by this author Raymond Lance More articles by this author Jonathan Wright More articles by this author Janet Stanford More articles by this author Expand All Advertisement PDF downloadLoading ...